What Is MRNA (Moderna) Stock? Ticker, Price History, and Why It Doubled in 2026

MRNA is the Nasdaq ticker symbol for Moderna, Inc., a biotechnology company that develops medicines and vaccines based on messenger RNA technology. The ticker is easy to confuse with the molecule it references: mRNA (messenger RNA) is the genetic material Moderna's science is built on, while MRNA is the stock you can buy and sell. This article covers the stock.

Moderna became a household name during the COVID-19 pandemic, when its Spikevax vaccine turned the company from a clinical-stage biotech into one of the most watched stocks on the Nasdaq. After a steep multi-year decline as pandemic revenue faded, MRNA staged one of the most dramatic comebacks of 2026, capped by a move that more than doubled the stock intraday on August 19, 2026.

Key Takeaways

• MRNA is the Nasdaq ticker for Moderna, Inc., a biotech built on messenger RNA technology. The ticker refers to the stock; mRNA refers to the molecule.
• Moderna stock more than doubled on August 19, 2026 after its personalized cancer vaccine with Merck succeeded in a Phase 3 melanoma trial, reaching a 52-week high of $163.47.
• The rally compounded an existing recovery: the FDA approved mFLUSIVA, the first mRNA flu vaccine in the United States, in early August 2026, giving Moderna its fourth approved product.
• Moderna pays no dividend and remains unprofitable, with analysts projecting limited revenue from its newest products before 2027.
• MRNA traveled from a 52-week low of $22.28 to over $160 within a year, making it one of the most volatile large-cap biotech stocks in the market.

Why Did Moderna Stock Double in August 2026?

On August 19, 2026, Moderna and its partner Merck announced positive topline results from INTerpath-001, a Phase 3 trial of intismeran autogene (mRNA-4157), a personalized mRNA cancer vaccine, combined with Merck's immunotherapy Keytruda. The companies reported that the combination reduced melanoma recurrence and spread compared with Keytruda alone in 1,137 patients with high-risk stage IIB to IV melanoma after surgery.

The market response was immediate. MRNA shares more than doubled intraday, touching a 52-week high of $163.47 after closing the previous day at $62.96. Merck shares also climbed on the news, though the move was smaller relative to its much larger market capitalization.

The science behind the reaction is what makes this readout different from a typical trial result. Intismeran is built individually for each patient: doctors sequence the mutations in a patient's tumor, and Moderna manufactures a custom mRNA shot encoding up to 34 tumor-specific targets called neoantigens. A successful Phase 3 result is the strongest evidence to date that this personalized approach works in a large population, and Merck and Moderna are already testing the same platform in lung, bladder, and kidney cancer trials.

The Setup Before the Spike

The melanoma readout landed on a stock that was already running. Three things set the stage:

The mFLUSIVA approval. In early August 2026, the FDA approved mFLUSIVA (mRNA-1010), Moderna's seasonal flu vaccine, for adults 50 and older. It is the first mRNA-based flu shot cleared in the United States, based on a Phase 3 trial of more than 40,000 participants across 11 countries. The approval was especially notable because the FDA had issued a refusal-to-file letter in February 2026 before reversing course, so clearance removed a major overhang.

A fourth approved product. mFLUSIVA gives Moderna four US-approved products and a respiratory vaccine lineup spanning COVID-19, RSV, and flu, shifting the company toward steadier seasonal demand rather than pandemic-driven spikes.

A deep base. MRNA hit a 52-week low of $22.28 in November 2025. The stock had already been climbing steadily through 2026 before the melanoma news, so the August 19 move compounded an existing recovery rather than starting one.

What Does Moderna Do?

Moderna develops medicines that use messenger RNA to instruct the body's own cells to produce proteins, whether that is a viral antigen for a vaccine or a set of tumor targets for cancer immunotherapy. The platform's appeal is speed and flexibility: the same manufacturing approach can, in principle, be redirected at new diseases far faster than traditional drug development.

The company's revenue today still comes primarily from respiratory vaccines. The oncology program with Merck is the pipeline's most valuable long-term bet, and the August 2026 melanoma data is the first Phase 3 validation of that bet.

Key Risks for MRNA Stock

Biotech stocks move on binary events, and Moderna is a case study in both directions. Points investors weigh:

Revenue timing. Analysts project little revenue from the new products before 2027. mFLUSIVA targets a commercial launch for the 2026-27 flu season, and a cancer vaccine approval, if it comes, is further out.

Profitability. Moderna remains unprofitable, with 2025 revenue of $1.9 billion, largely from COVID vaccines. Its annual report states it expects additional losses and may not achieve long-term sustainable profitability.

Clinical risk. Trial outcomes can reverse sentiment fast: in October 2025, Moderna's Phase 3 CMV vaccine study missed its primary endpoint and the program was discontinued in its lead population. mFLUSIVA's accelerated approval for adults 65 and older also depends on a confirmatory study.

Manufacturing complexity. Intismeran is built individually for each patient through a novel, complex process, and Moderna flags in its annual report that it may encounter difficulties in production.

Volatility. A stock that traveled from $22.28 to $163.47 within a year can retrace just as sharply. Moderna itself lists stock price volatility as a material risk in its annual report.

How to Buy MRNA Stock on Backpack

Eligible users can buy MRNA on Backpack in a few simple steps.

1. Create and verify a Backpack account. Identity verification is required before trading.
2. Deposit funds. Stock purchases are funded from your available USD balance. You can deposit USD via USDC across supported networks, or via USD wire transfer from your bank account.
3. Search for MRNA. Find Moderna by its ticker in the markets list.
4. Place an order. Enter your amount and confirm.

MRNA on Backpack can be traded 24 hours a day, 5 days a week, from Sunday 8:00 pm to Friday 8:00 pm Eastern Time, across overnight, pre-market, regular, and after-hours sessions. For a stock like Moderna, that reach matters: the INTerpath-001 results broke before US markets opened, and FDA decisions routinely land outside standard trading hours.